Rankings
▼
Calendar
IBRX
ImmunityBio, Inc.
$8B
Q4 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$12,000
-14.3% YoY
Gross Profit
$12,000
100.0% margin
Operating Income
-$25M
-205208.3% margin
Net Income
-$24M
-204058.3% margin
EPS (Diluted)
$-0.08
QoQ Revenue Growth
+50.0%
Cash Flow
Operating Cash Flow
-$14M
Free Cash Flow
-$25M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$250M
Total Liabilities
$32M
Stockholders' Equity
$219M
Cash & Equivalents
$24M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$12,000
$14,000
-14.3%
Gross Profit
$12,000
$14,000
-14.3%
Operating Income
-$25M
-$24M
-1.1%
Net Income
-$24M
-$24M
-1.0%
Geographic Segments
San Diego California
$100,000
100%
← FY 2017
All Quarters
Q1 2018 →
IBRX Q4 2017 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena